Introduction {#Sec1}
============

Compromised renal elimination of phosphate leads in chronic kidney disease (CKD) to increase of phosphate concentration in plasma and tissues which in turn triggers vascular calcification leading to cardiovascular events and the respective increases of morbidity and mortality^[@CR1]--[@CR4]^. Calcium deposition in the vascular wall involves osteo-/chrondrogenic reprogramming of vascular smooth muscle cells (VSMCs)^[@CR5]--[@CR8]^. The signaling includes up-regulation of the transcription factor NFAT5 (nuclear factor of activated T cells 5)^[@CR9]--[@CR12]^. NFAT5 was originally cloned as tonicity responsive enhancer binding protein (TonEBP) stimulated by hyperosmotic cell shrinkage^[@CR13],[@CR14]^ and subsequently been shown to be enhanced in several disorders, such as diabetes^[@CR15]^, inflammation^[@CR16]^ and CKD^[@CR12]^.

NFAT5-regulated genes include SGK1 (serum and glucocorticoid inducible kinase 1)^[@CR17]^. SGK1 up-regulates the transcription factor NFκB (nuclear factor κB)^[@CR18]^. NFκB triggers transcription of the Ca^2+^-channel ORAI1. Following depletion of intracellular Ca^2+^-stores ORAI1 is activated by Ca^2+^ sensing STIM (stromal interaction molecules)^[@CR18]^. Opening of ORAI1 by STIM leads to the so-called store operated Ca^2+^-entry (SOCE)^[@CR18]^, SOCE is a powerful mechanism activating blood platelets^[@CR19],[@CR20]^. Genetic or pharmacological knockout of SGK1 down-regulates ORAI1^[@CR21]^, blunts platelet activation^[@CR22],[@CR23]^ and thus counteracts thrombosis^[@CR23]^ and arteriosclerosis^[@CR24]^. SGK1 and thus SGK1-dependent up-regulation of ORAI1 expression is stimulated by ischemia, oxidative stress, hyperglycemia, advanced glycation end products (AGEs) and several mediators including glucocorticoids, mineralocorticoids, transforming growth factor beta (TGFβ), interleukin 6 (IL-6), platelet-derived growth factor (PDGF), thrombin and endothelin^[@CR25]^. By stimulating ORAI1 expression, upregulated SGK1 may increase the risk of thrombo-occlusive events in diabetes mellitus, inflammation, and chronic kidney disease^[@CR20],[@CR24],[@CR25]^.

Platelets are released into the blood stream by megakaryocytes, which differentiate from hematopoietic progenitor cells in the bone marrow^[@CR26],[@CR27]^. Megakaryocytes reorganize their cytoplasm into long proplatelet extensions that release platelets into the circulation^[@CR27]^. Consequently, the proteins expressed in megakaryocytes are expected to be transferred into circulating blood platelets^[@CR27]^. Recent observations revealed a powerful SGK1 dependent stimulation of ORAI1 expression by NFAT5 overexpression in megakaryocytes^[@CR28]^.

In view of those observations we hypothesized that the phosphate-donor ß-glycerophosphate mimicking enhanced extracellular phosphate concentration may up-regulate the expression of NFAT5 in megakaryocytes, and that NFAT5 enhances the expression of SGK1, ORAI1 and STIM1 and/or STIM2. Considering that the abundance of the respective proteins in circulating platelets is a function of protein synthesis in megakaryocytes, enhanced extracellular phosphate may up-regulate the expression of NFAT5, SGK1, ORAI1 and STIM1 and/or STIM2 in circulating blood platelets. To the best of our knowledge, however, nothing is hitherto known on the contribution of NFAT5 to the regulation of megakaryocyte or platelet function in CKD patients.

The present study thus explored whether NFAT5, SGK1, ORAI1, ORAI2, ORAI3 STIM1 and/or STIM2 expression in megakaryocytes is sensitive to phosphate-donor ß-glycerophosphate and altered in patients with CKD incl. dialysis-dependency.

Results {#Sec2}
=======

As the transcription factor NFAT5 is known to upregulate expression of SGK1^[@CR17]^ which in turn activates transcription factor NFkB with upregulation of ORAI and STIM isoform expression^[@CR18]^, the present study explored whether the phosphate donor ß-glycerophosphate modifies the transcript levels of the transcription factor nuclear factor of activated T cells 5 (NFAT5), of the NFAT5-regulated serum & glucocorticoid inducible kinase 1 (SGK1), of the SGK1-sensitive Ca^2+^ release activated ion channels ORAI1, ORAI2 and ORAI3 as well as of the ORAI activating Ca^2+^ sensor isoforms STIM1 and STIM2. As illustrated in Fig. [1](#Fig1){ref-type="fig"}, 24 hours exposure of human megakaryocytes to 2 mM ß-glycerophosphate was followed by a significant increase in the transcript levels of NFAT5, SGK1, ORAI1, ORAI2, ORAI3, STIM1, and STIM2 (Fig. [1A--G](#Fig1){ref-type="fig"}). As illustrated in Fig. [1H](#Fig1){ref-type="fig"}, exposure to 2 mM ß-glycerophosphate further increases the transcription of fibroblast growth factor 23 (FGF23), a gene sensitive to ORAI1-dependent Ca^2+^ entry into UMR106 bone cells^[@CR29]^.Figure 1ß-glycerophosphate-sensitive NFAT5, SGK1, ORAI1, ORAI2, STIM1, STIM2 and FGF23 transcription in megakaryocytes (**A--E**). Arithmetic means (±SEM, n = 4--7) of NFAT5 (**A**), SGK1 (**B**), ORAI1 (**C**), ORAI2 (**D**), ORAI3 (**E**), STIM1 (**F**), STIM2 (**G**) and FGF23 (**H**) transcript levels in megakaryocytes without (white bars) and with (black bars) prior exposure to 2 mM ß-glycerophosphate for 24 hours. \*(p \< 0.05), \*\*(p \< 0.01) indicates statistically significant difference to respective value without prior ß-glycerophosphate treatment (Student's t-test).

In order to test, whether the enhanced expression of ORAI and STIM isoforms is followed by the respective alterations of Ca^2+^ signaling, Fura2 fluorescence was utilized to determine the cytosolic Ca^2+^ activity (\[Ca^2+^\]~i~). The 340 nm/380 nm ratio reflecting \[Ca^2+^\]~i~ was, prior to store depletion, similar in ß-glycerophosphate treated (0.425 ± 0.030, n = 7) and in untreated (0.459 ± 0.046, n = 7) megakaryocytes. For determination of SOCE, cells were exposed to thapsigargin (1 µM), a sarco-/endoplasmic reticulum Ca^2+^/ATPase (SERCA) inhibitor, and Ca^2+^-free solutions to deplete intracellular Ca^2+^ stores. In the following extracellular Ca^2+^ was re-added in the continued presence of thapsigargin to quantify SOCE from the increase of \[Ca^2+^\]~I~ (Fig. [2A](#Fig2){ref-type="fig"}). As illustrated in Fig. [2A,C--E](#Fig2){ref-type="fig"}, ß-glycerophosphate pretreatment significantly increased both peak and slope of SOCE. SOCE was significantly decreased by the selective ORAI1 inhibitor MRS1845 (10 µM) (Supplementary Fig. [3](#MOESM1){ref-type="media"}). The 340 nm/380 nm ratio was similar prior to (0.444 ± 0.016, n = 4) and 3 min following (0.495 ± 0.022, n = 4) acute administration of 2 mM ß-glycerophosphate in the presence of extracellular Ca^2+^ (Supplementary Fig. [4](#MOESM1){ref-type="media"}). Moreover, a 30 min pretreatment with 2 mM ß-glycerophosphate did not significantly modify SOCE (Supplementary Fig. [5](#MOESM1){ref-type="media"}).Figure 2ß-glycerophosphate-sensitive intracellular Ca^2+^ release and store-operated Ca^2+^ entry (SOCE) in Meg01 cells. (**A**). Representative tracings of Fura-2 fluorescence-ratio in fluorescence spectrometry before and following extracellular Ca^2+^ removal and addition of thapsigargin (1 µM), as well as re-addition of extracellular Ca^2+^ in Meg01 cells without (control, white circles) or with (black circles) prior exposure to 2 mM ß-glycerophosphate for 24 hours. (**B,C**). Arithmetic means (±SEM, n = 56--52 cells from 7 groups) of peak (**B**) and slope (**C**) increase of fura-2-fluorescence-ratio following addition of thapsigargin (1 µM) in Meg01 cells without (control, white bars) or with (black bars) prior exposure to 2 mM ß-glycerophosphate for 24 hours. (**D,E**). Arithmetic means (±SEM, n = 56--52 cells from 7 groups) of peak (**D**) and slope (**E**) increase of fura-2-fluorescence-ratio following re-addition of extracellular Ca^2+^ in Meg01cells without (control, white bars) or with (black bars) prior exposure to 2 mM ß-glycerophosphate for 24 hours. \*(p \< 0.05), \*\*\*(p \< 0.0005) indicates statistically significant difference to respective value without prior ß-glycerophosphate treatment (Student's t- test).

In order to test, whether the observed upregulation of NFAT5, SGK1, ORAI1, ORAI2, STIM1 and STIM2 by ß-glycerophosphate in megakaryocytes leads to the respective alterations of transcript levels in circulating blood platelets, the cells were isolated from patients with impaired kidney function and control volunteers with normal kidney function. Supplementary Fig. [2](#MOESM1){ref-type="media"} displays creatinine plasma levels, glomerular filtration rate (GFR), as well as numbers of leukocytes and platelets in blood from control volunteers and patients with impaired kidney function. As illustrated in Fig. [3](#Fig3){ref-type="fig"}, the transcript levels of NFAT5, SGK1, ORAI1, ORAI2, and STIM2 were significantly higher in blood platelets from patients with impaired kidney function than in platelets from control volunteers. As illustrated in Fig. [4](#Fig4){ref-type="fig"}, NFAT5, SGK1, ORAI isoforms and STIM isoforms transcript levels were negatively correlated with GFR, i.e. a decline of GFR was associated with enhanced transcript levels of NFAT5, SGK1, ORAI1, ORAI2, STIM1 and STIM2.Figure 3NFAT5, SGK1, ORAI1, STIM1, ORAI2 transcript levels in platelets from control volunteers and patients with chronic kidney disease. (**A--G**). Single values and arithmetic means (±SEM) of (**A**) NFAT5, (**B**) SGK1, **(C)** ORAI1, (**D**) ORAI2, (**E**) ORAI3, (**F**) STIM1, and (**G**) STIM2 transcript levels in platelets drawn from control volunteers (white circles) or patients with impaired kidney function (black squares).Figure 4Correlation between GFR and NFAT5, SGK1, ORAI1, STIM1, ORAI2 transcript levels in platelets from control volunteers and patients with chronic kidney disease. (**A--G**). Single values of (**A**) NFAT5, (**B**) SGK1, **(C)** ORAI1, (**D**) ORAI2 (**E**), Orai3 (**F**), STIM1, and (**G**) STIM2 transcript levels in platelets drawn from control volunteers (white circles) or patients with impaired kidney function (black circles) as a function of GFR.

Western blotting was employed in order to test, whether the enhanced NFAT5 and ORAI1 transcript levels in patients with impaired kidney function are paralleled by the respective alterations of protein abundance. As illustrated in Fig. [5](#Fig5){ref-type="fig"}, both, NFAT5 and ORAI1 protein abundance was significantly higher in platelets from patients with impaired kidney function than in platelets from control volunteers.Figure 5NFAT5 and ORAI1 protein abundance in platelets from control volunteers and patients with chronic kidney disease. (**A--C**). Original Western blots of (**A**) NFAT5 and **(C)** ORAI1 protein abundance in platelets drawn from control volunteers (**B--D**). Arithmetic means (±SEM) of (**B**) NFAT5 and **(D)** ORAI1 protein abundance in platelets drawn from control volunteers (white circles) or patients with impaired kidney function (black squares).

Discussion {#Sec3}
==========

The present study discloses a novel effect of the phosphate donor ß-glycerophosphate in megakaryocytes, i.e. the upregulation of ORAI1, ORAI2, ORAI3, STIM1 and STIM2 expression. ORAI1 is a Ca^2+^ channel^[@CR22]^ shown to accomplish store operated Ca^2+^ entry (SOCE) in multiple cell types^[@CR30]^ including platelets^[@CR20]^ and megakaryocytes^[@CR22]^. To the best of our knowledge, an effect of phosphate or of phosphate donor ß-glycerophosphate on ORAI, STIM and their isoforms has never been shown before in megakaryocytes or platelets.

The effect of phosphate-donor ß-glycerophosphate is disrupted by pharmacological inhibition of SGK1 and is thus presumably due to upregulation of SGK1 by NFAT5. NFAT5 has previously been shown to increase the expression of SGK1^[@CR17]^, which is known to trigger the degradation of the inhibitor protein IκBα thus allowing nuclear translocation of the transcription factor NFκB^[@CR18]^. Genes up-regulated by NFκB include ORAI1^[@CR18]^.

In view of the upregulation of NFAT5, SGK1, ORAI1, STIM1 and STIM2 expression in megakaryocytes by the phosphate donor ß-glycerophosphate, the transcript levels of NFAT5, SGK1, ORAI1, ORAI2, ORAI3, STIM1 and STIM2 were expected to be enhanced in platelets from patients with impaired kidney function. As a matter of fact, the transcript levels of each, NFAT5, SGK1, ORAI1, ORAI2, STIM1and STIM2 were significantly higher in platelets isolated from patients with impaired kidney function than in platelets isolated from control volunteers. As shown for NFAT5 and ORAI1, the increase of transcript levels is paralleled by the respective increase of protein abundance. NFAT5 expression has been shown to be upregulated by patients with advanced CKD incl. dialysis-dependency in other cell types^[@CR12]^, but not in megakaryocytes or blood platelets.

The upregulation of ORAI1 and STIM2 in platelets of CKD patients is expected to sensitize the platelets for activators^[@CR31]^. The presently observed stimulation of ORAI1 and STIM2 could thus contribute to the known high risk of cardiac infarction and stroke in CKD patients^[@CR32],[@CR33]^. Excessive activation of blood platelets is well known to enhance the risk of cardiac infarction and stroke^[@CR34]^. Additional effort is needed to define the contribution of phosphate-sensitive ORAI1 and STIM2 expression in blood platelets to the enhanced cardiovascular risk in patients with advanced CKD.

As shown for other cell types, NFAT5 is up-regulated in further clinical disorders, such as dehydration^[@CR11]^, diabetes mellitus^[@CR15]^ and inflammatory disease^[@CR16]^. In those conditions the enhanced NFAT5 expression may lead to stimulation of SGK1 expression with subsequent upregulation of ORAI1, STIM1 and STIM2 in megakaryocytes and sensitization of blood platelets to activating stimuli. The signalling may again involve SGK1-sensitive degradation of the inhibitor protein IκBα thus allowing nuclear translocation of the transcription factor NFκB.

ORAI1 expression and thus SOCE may be sensitive to phosphate or ß-glycerophosphate in other cell types. The ORAI^[@CR35]--[@CR39]^ and STIM^[@CR40]--[@CR44]^ isoforms accomplish store operated Ca^2+^ entry (SOCE) in a myriad of cell types. Alterations of cytosolic Ca^2+^ activity in turn contribute to the regulation of diverse cellular functions including excitation, exocytosis, migration, cell proliferation and cell death^[@CR45]--[@CR49]^. Notably, ORAI1 and STIM1 are expressed in lymphocytes thus participating in the orchestration of immune response and inflammation^[@CR50],[@CR51]^. The overexpression of ORAI1 and STIM1 in tumor cells contributes to cancer growth^[@CR52]--[@CR56]^. Future experimental effort will be required to define the pathophysiological impact of phosphate sensitive ORAI and STIM expression on inflammation and malignancy in CKD.

Genes previously shown to be upregulated by NFAT5, SGK1, ORAI1, ORAI2, STIM1 and STIM2 in UMR106 cells include FGF23^[@CR29]^. Here we demonstrate that the phosphate donor ß-glycerophosphate upregulates FGF23 in megakaryocytes. In view of the putative influence of SOCE on FGF23 transcription in UMR106 cells^[@CR29]^, it is tempting to speculate that the observed signaling contributes to the phosphate-induced FGF23 release from bone. Whether ORAI1 expression and function is sensitive to phosphate in UMR106 cells remains, however, to be shown.

In conclusion, the phosphate donor ß-glycerophosphate stimulates the expression of NFAT5, SGK1, ORAI and STIM isoforms and thus store operated Ca^2+^ entry (SOCE) into megakaryocytes (Fig. [6](#Fig6){ref-type="fig"}). Accordingly, NFAT5, SGK1, ORAI and STIM isoform expression is enhanced in platelets of patients with impaired kidney function and could thus contribute to the enhanced cardiovascular risk in those patients.Figure 6Diagram depicting the signaling events generated by treatment of Meg01 cells with ß-glycerophosphate (2beta-GP).

Materials and Methods {#Sec4}
=====================

Patients and volunteers {#Sec5}
-----------------------

11 patients (8♂, 3♀) with impaired kidney function and 12 volunteers with normal kidney function (9♂, 3♀) have been enrolled in the study. The patients were recruited from the Department of Internal Medicine, University Hospital Tuebingen. The study was performed in accordance to the approval by ethics committee of the University of Tübingen (270/2011BO1) and in accordance with the Declaration of Helsinki. Informed written consent was provided by both, volunteers and patients. Clinical details of the patients are compiled in Table [1](#Tab1){ref-type="table"}.Table 1Recruited patients with advanced CKD incl. dialysis-dependency and control volunteers.ParametersAll PatientsRenal impairmentControlp valuen = 23 (100%)n = 11 (48%)n = 12 (52%)**Clinical characteristics**Age68.5 ± 3.472.4 ± 2.80.38Creatinine4.2 ± 0.851.1 ± 0.080.0011GFR19.2 ± 3.165.1 ± 5.70.0001CRP1.3 ± 0.42.0 ± 0.70.4098Hb11.6 ± 0.511.9 ± 0.60.7057WBC8517 ± 7267779 ± 4090.3756platelets197.9 ± 17.8214.8 ± 18.10.5156female3 (27%)3 (25%)1Dialysis4 (36%)0 (0%)0.0373Diabetes6 (55%)5 (42%)0.6843Hypertension10 (91%)10 (83%)1**Medication**Betablockers8 (73%)10 (83%)0.6404Statin9 (82%)10 (83%)1ACE-Inh.4 (36%)4 (33%)1AT-1 Inh.2 (18%)3 (25%)1ASA6 (55%)7 (58%)1Clopidogrel3 (27%)2 (17%)0.6404Ticagrelor2 (18%)5 (42%)0.3707Phenprocoumon0 (0%)1 (8%)1DOAK1 (9%)1 (8%)1

Preparation of human platelets {#Sec6}
------------------------------

Venous blood was drawn into tubes containing acid/citrate/dextrose buffer, from the antecubital vein of volunteers and patients with impaired kidney function. Platelet-rich plasma (PRP) was removed by centrifugation at 430 × g for 20 min. PRP was centrifuged at 900 × g for 10 min after adding Tyrodes/HEPES buffer (2.5 mmol/liter HEPES, 1 mmol/liter KCl, 2.5 mmol/liter NaHCO~3~, 150 mmol/liter NaCl, 0.36 mmol/liter NaH~2~PO~4~, 5.5 mmol/liter glucose, and 1 mg/ml BSA, pH 6.5). The platelets were resuspended after removing supernatant, in 200 µl of Tyrodes/HEPES buffer (supplemented with 1 mmol/liter CaCl~2,~ pH 7.4) and used for RNA/protein isolation. \~98% purity of the platelet preparation was obtained as determined by a Haematology Analyser (Sysmex KX219, Sysmex Germany GmbH).

Cell culture {#Sec7}
------------

Human megakaryocytic cells (Meg01) from ATCC (American Type Culture Collection, Manassas, VA, USA) were cultured in RPMI 1640 (Roswell Park Memorial Institute medium, Gibco Thermo Fischer Scientific, Paisley, United Kingdom) containing 10% FBS and 1% Penicillin/Streptomycin in humidified incubator at 37 °C and 5% CO~2~. Where indicated, the cells were exposed to 2 mM ß-glycerophosphate (Sigma, Steinheim, Germany) for 24 hours in the absence and presence of ORAI1 inhibitor MRS1845 (10 µM) (Tocris, Bristol, United Kingdom). In the analysis of vascular calcification, phosphate donor ß-glycerophosphate is widely used as substitute for phosphate and well established stimulator of tissue calcification^[@CR57]--[@CR59]^.

Quantitative PCR {#Sec8}
----------------

To determine transcript levels of NFAT5, ORAI1, ORAI2, ORAI3, STIM1, STIM2 and FGF23 total RNA was extracted according to manufacturer's instructions with TriFast (Peqlab, Erlangen, Germany)^[@CR60]--[@CR64]^. DNAse digestion was performed to avoid DNA contamination and was followed by reverse transcription using random hexamers (Promega, Manheim, Germany) and GoScript™ reverse transcription system (Promega, Manheim, Germany). Real-time polymerase chain reaction (RT-PCR) amplification of the respective genes were set up in a total volume of 20 µl using 40 ng of cDNA, 500 nM forward and reverse primer and 2x GoTaq® qPCR Master Mix (Promega, Hilden, Germany) following manufacturer's protocol. Cycling conditions were as follows: initial denaturation at 95 °C for 2 minutes, followed by 40 cycles of 95 °C for 15 seconds, 55 °C for 15 seconds and 68 °C for 20 seconds. For amplification the following primers were used (5′- \> 3′ orientation) (Invitrogen, Carlsbad, CA, USA)):

NFAT5

fw: GAGCAGAGCTGCAGTAT

rev: AGCTGAGAAAGCACATAG

GAPDH:

fw: TGAGTACGTCGTGGAGTCCAC

rev: GTGCTAAGCAGTTGGTGGTG

ORAI1:

fw: CGTATCTAGAATGCATCCGGAGCC

rev: CAGCCACTATGCCTAGGTCGACTAGC

ORAI2:

fw: CAGCTCCGGGAAGGAACGTC

rev: CTCCATCCCATCTCCTTGCG

ORAI3:

fw:CTTCCAATCTCCCACGGTCC

rev:GTTCCTGCTTGTAGCGGTCT

SGK1:

fw:TTCCTATCGCAGTGTTTCAGTTCTT

rev:CACACTCACACGACGGTTCAC

STIM1:

fw: CCTCGGTACCATCCATGTTGTAGCA

rev: GCGAAAGCTTACGCTAAAATGGTGTCT

STIM2:

fw: CAAGTTGCCCTGCGCTTTAT

rev: ATTCACTTTTGCACGCACCG

FGF23:

fw: ATGAGCGTCCTCAGAGCCTA

rev: AGACGTCGTACCCGTTTTCC

Melting curves were analysed to confirm PCR product specificity. CFX96 Real-Time System (BioRad, Munich, Germany) was used to perform real-time PCR amplifications and all experiments were done in duplicate. The house-keeping gene Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was amplified to standardize the amount of sample RNA.

Western blotting {#Sec9}
----------------

Protein abundance of NFAT5, ORAI1, and GAPDH was determined by Western blotting^[@CR60]--[@CR64]^. After isolation of platelets from control donors and patients with impaired kidney function, platelets were centrifuged for 5 minutes at 600 g and 4 °C. The pellet was washed with ice cold PBS and suspended in 50 μl ice-cold RIPA lysis buffer (Cell Signalling Technology, USA) containing Protease Inhibitor Cocktail (Sigma-Aldrich, Taufkirchen, Germany). After centrifugation (20,000 g, 4 °C for 20 minutes) the supernatant was taken to determine protein concentration using the Bradford assay (BioRad, München, Germany). For Western blotting 50 µg of protein were electro-transferred onto a nitrocellulose membrane after electrophoresis using 12% SDS- PAGE and blocked with 5% milk in TBST at room temperature for 1 h. The membranes were incubated with primary anti-NFAT5 antibody (1:1000, Novus Biologicals), anti-ORAI1 antibody (1:1000, Proteintech, Chicago, USA) and anti-GAPDH antibody (1:1000, Cell Signaling, Danvers, USA) at 4 °C overnight. After washing (TBST), the blots were incubated with secondary anti-rabbit antibody conjugated with horseradish peroxidase (1:1000, Cell Signaling, Danvers, USA) for 1 h at room temperature. Protein bands were detected after additional washes (TBST) with an ECL detection reagent (Amersham, Freiburg, Germany). For densitometry image analysis, western blots were scanned and analyzed by ImageJ software (NIH, USA), and the results are shown as the ratio of total protein to GAPDH normalized to the control group. Protein-Marker VI (Peqlab, Erlangen, Germany) was used as reference to assign the right protein size.

Calcium measurements in megakaryocytes {#Sec10}
--------------------------------------

To determine cytosolic Ca^2+^ concentration (\[Ca^2+^\]~i~), Fura-2/AM fluorescence was utilized^[@CR60]--[@CR65]^. Cells were preincubated for 15--30 minutes with Fura-2/AM (2 µM, Invitrogen, Goettingen, Germany) at 37 °C and excited alternatively at 340 nm and 380 nm in an inverted phase-contrast microscope (Axiovert 100, Zeiss, Oberkochen, Germany) through an objective (Fluor 40×/1.30 oil). At 505 nm, the emitted fluorescence intensity was recorded. Data (6/minute) were acquired using a computer software Metafluor (Universal Imaging, Downingtown, USA). To estimate cytosolic Ca^2+^ activity, a ratiometer (340 nm/380 nm) based analysis was employed. SOCE was determined following extracellular Ca^2+^ removal causing store depletion and subsequent Ca^2+^ re-addition in constant presence of SERCA inhibitor thapsigargin (1 µM, Invitrogen,Goettingen, Germany). For quantification of Ca^2+^ entry, the slope (delta ratio/s) and peak (delta ratio) were determined following re-addition of Ca^2+^. Experiments were performed with Ringer's solution containing (in mM): 125 NaCl, 5 KCl, 1 CaCl~2~, 32 HEPES, 2 Na~2~HPO~4~, 1.2 MgSO~4~, 5 glucose, pH 7.4. Ca^2+^-free conditions were achieved by using Ca^2+^-free Ringer solution containing (in mM): 125 NaCl, 5 KCl, 1.2 MgSO~4~, 2 Na~2~HPO~4~, 32 HEPES, 0.5 EGTA, 5 glucose, pH 7.4.

Statistical analysis {#Sec11}
--------------------

Data are provided as means ± SEM, *n* represents the number of independent experiments (i.e. in fluorescence experiments the number of dishes measured). Patient data are shown in scatter plots to illustrate the scatter of the data between patients. All data were tested for significance using unpaired t-test (Student's t-test) or ANOVA. Results with p \< 0.05 were considered statistically significant.

Ethical permission {#Sec12}
------------------

The study was approved by the ethics committee of the University of Tuebingen (270/2011BO1) and has been executed in accordance with the Declaration of Helsinki. Both, volunteers and patients provided informed written consent. The data have been presented at a conference^[@CR66]^.
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